Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 12, 2017 - Issue
Submit an article Journal homepage
69
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease

Kyung Hoon Kim1 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul
,
Hye Seon Kang2 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon
,
Ju Sang Kim3 Division of Pulmonary Medicine, Department of Internal Medicine, Incheon St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon
,
Hyoung Kyu Yoon4 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul
,
Sung Kyoung Kim5 Division of Pulmonary Medicine, Department of Internal Medicine, St Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of KoreaCorrespondence[email protected]
&
Chin Kook Rhee1 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, SeoulCorrespondence[email protected]
Pages 3449-3456 | Published online: 04 Dec 2017

References

  • MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med20063e44217132052
  • Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
  • TashkinDPRoflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPDExpert Opin Pharmacother201415859624032576
  • RabeKFBatemanEDO’DonnellDWitteSBredenbrokerDBethkeTDRoflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet200536656357116099292
  • CalverleyPMSanchez-TorilFMcIvorATeichmannPBredenbroekerDFabbriLMEffect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007176215416117463412
  • CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJM2-124 and M2-125 study groupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
  • FabbriLMCalverleyPMIzquierdo-AlonsoJLM2-127 and M2-128 study groupsRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
  • MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
  • WorndlEHuntEBKennedyMKPlantBJHenryMTMurphyDMReal-life experience with roflumilast therapy in COPD patients at Cork University HospitalIrish J Med Sci2014183S506S507
  • WorndlEHuntEBKennedyMPHenryMTPlantBJMurphyDMRoflumilast in COPDChest2015148e31
  • GiembyczMAFieldSKRoflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPDDrug Des Dev Ther20104147158
  • KimMKLeeWYKangJHClinical practice guidelines for overweight and obesity in KoreaEndocrinol Metab (Seoul)201429440540925559568

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.